65,437 trials
Functional Bowel Disorder
Primary: Change From Baseline of Sum of NRS-11 Abdominal Pain and Bloating/Flatulence Intensity Scores After 4 Weeks of Treatment. — -7.23; -6.48; -5.86 score on a scale — p=0.0042
Aging
Primary: Change of Daily Step Counts From Baseline — 842; 194; 1099; 408 Steps per day — p=0.009
Visual Acuity
Primary: Proportion of Eyes With LogMAR Visual Acuity Less Than 0.176 (20/30 Snellen Acuity) — 1; 1 Proportion of eyes
Concussion, Brain
Primary: Persistent Post Concussion Symptoms (PPCS) (Yes/No) — 4; 4 Participants
Pain
Primary: Self Reported Pain Rating Using Wong-Baker FACES Scale — 3.57; 5.13 score on a scale
Cigarette Smoking-Related Carcinoma
Primary: Number of Unique App Sessions — 29.6; 24.3 number of sessions
Dementia
Primary: Time to Nursing Home Placement — 172.0725; 165.0270 Days
Chronic Pain
Primary: The Degree of Effectiveness of Acceptance and Commitment Therapy: [Impact] — 23.9; 21.4; 41.7; 37.5 units on a scale — p=0.82
Mal de Debarquement Syndrome (MdDS)
Primary: Subjective Symptoms Self-report of Overall Severity — 5.2; 5.2; 3.2; 2.1 score on a scale
Tobacco Use Disorder · Smoking Cessation · Tobacco Use Cessation
Primary: Change in Use of Smoking Cessation Pharmacotherapy in Past 30 Days — 11; 9; 9; 2 Participants
Abuse Potential
Primary: Drug Liking "at This Moment" Visual Analog Scale (VAS) — 54.1; 83.8; 58.9; 58.4 score on a scale
Eosinophilic Duodenitis · Eosinophilic Gastroenteritis
Primary: Proportion of Tissue Eosinophil Responders at Week 24 — 38; 2 Participants — p=<0.0001
Type 1 Diabetes
Primary: Glucose Time in Range — 46; 49 percentage of time in range
Healthy Volunteer
Primary: Microneutralization Titers — 0.769; 1.313; 1.716; 1.333 Log2 Fold Change
Bladder Urothelial Carcinoma In Situ · Recurrent Bladder Urothelial Carcinoma · Stage 0a Bladder Cancer AJCC v8
Primary: Trial Recruitment: Number of Participants Eligible, Enrolled, and Not Enrolled — 45; 0; 3; 2 Participants